Previous 10 | Next 10 |
Lineage Cell Therapeutics (LCTX) formal corporate presentation from NobleCon18 - Noble Capital Markets 18th Annual Small & Microcap Investor Conference - April 2022. Read More >>
Fireside Chat with B. Riley Research Analyst Scheduled for 3:30pm Eastern Time Topics Will Include Two New Cell Therapy Programs Launched Following Roche and Genentech Partnership for RG6501 (OpRegen ® ) Program Lineage Cell Therapeutics, Inc. (NYSE Amer...
Photoreceptor Development Program Announced. Lineage Cell announced a new program to develop photoreceptor cells for transplantation. This is an additional application of Lineage's proprietary cell-based technology for growing pluripotent cells into differentiated cells that can be transplante...
Lineage Cell Therapeutics (NYSE:LCTX) announced a new cell therapy development program, photoreceptor neural cell (PNC) transplants to treat vision loss due to photoreceptor dysfunction or damage. The company said it filed for intellectual property protection covering the composition and meth...
Dynamic Culturing Process Developed by Lineage Offers Path to Clinical- and Industrial-Scale Production of Photoreceptors Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Cancer Research UK recently completed patient enrollment in the ongoing Phase 1 clinical tria...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, the Company’s Chief Executive Officer, will be presenting at NobleCon18...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, the Company’s Chief Executive Officer, will be presenting at the 2022 V...
Brian Culley, CEO of Lineage Cell Therapeutics, discusses developing and commercializing therapies to treat degenerative diseases. Competing against Elon Musk’s Neuralink; strategic advantages. Adjusting to global supply chain shortages and the future of cell and gene thera...
A New Pipeline Product Has Been Added. Lineage Cell announced that it has added a new program in auditory neuronal cell transplants for the treatment of hearing loss. The new development program will treat disorders in which the ear can detect sound, but the transmission of impulses to the bra...
News, Short Squeeze, Breakout and More Instantly...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE America...